SLC5A2 and hydrops fetalis: While several studies identified that all-cause mortality and cardiovascular mortality were comparable between patients on SGLT2 inhibitors and those on placebo [42], one study reported a significant reduction in all-cause mortality in HF patients (both HFpEF and HFrEF) treated with SGLT2 inhibitors [47].